Versiti Blood Research Institute.
Medical College of Wisconsin.
Blood. 2021 Feb 25;137(8):1006-1007. doi: 10.1182/blood.2020010459.
In this issue of , Althaus et al identify circulating procoagulant platelets as a novel biomarker of COVID-19 disease severity and present provocative in vitro findings demonstrating that antibodies induced in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can initiate procoagulant platelet formation.
在本期 中，Althaus 等人将循环促凝血小板确定为 COVID-19 疾病严重程度的新型生物标志物，并提出了一些有争议的体外研究结果，表明针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）产生的抗体可以引发促凝血小板形成。
